Pfizer Inc.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 3, 2026, Pfizer Inc. (the “Company”) announced that the Board of Directors of the Company unanimously elected Cecile Guegan to serve as Chief Financial Officer, Executive Vice President of the Company, effective November 1, 2026 (the “Effective Date”). As reported in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 18, 2026, Ms. Guegan, 55, was previously appointed as the Company’s Interim Chief Financial Officer, effective Aug... In connection with Ms. Guegan’s election, the Compensation Committee of the Board of Directors of the Company unanimously approved the following compensation arrangements for Ms. Guegan as of the Effective Date: (1) an annual base salary of $1,300,000; and (2) an annual target cash incentive opportunity of $1,300,000, which represents 100% of her annual base salary, which will be determined based on the salary paid during the year. A copy of the Company’s press release announcing Ms. Guegan’s appointment is attached as Exhibit 99.1 and is incorporated herein by reference.